New Keppra XR data highlight its role for patients with partial-onset seizures
Studies show Keppra XR reduces nervous system side effects compared to levetiracetam immediate release, and a new dosing schedule may offer improved tolerability. The once-daily formulation also demonstrates bioequivalence in healthy adults.